Last reviewed · How we verify
NCT05910710
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
trial testing Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS) in Triple Negative Breast Cancer in 50 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 2 March 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Conditions studied
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
- Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →
- Pembrolizumab — all drugs for Pembrolizumab →
- Tumor Microenvironment — all drugs for Tumor Microenvironment →
Sponsor
Samsung Medical Center
Who can join
19 and older, any sex, with Triple Negative Breast Cancer or Neoadjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer. (Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.
Kotsifaki A, Alevizopoulos N, Dimopoulou V, Armakolas A. · · 2023 · cited 28× · PMID 37895012 · DOI 10.3390/ijms242015332 -
Spatial omics technology potentially promotes the progress of tumor immunotherapy.
Lan Z, Yang Y, Li L, Wang C, et al · · 2025 · cited 2× · PMID 40456924 · DOI 10.1038/s41416-025-03075-5 -
Cell-cell interactions as predictive and prognostic markers for drug responses in cancer.
Lu X, Tan X, Kim EJ, Jin X, et al · · 2025 · cited 1× · PMID 41063141 · DOI 10.1186/s13073-025-01518-5
Verify or expand the search:
- PubMed search for NCT05910710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Triple Negative Breast Cancer
Currently open trials in the same condition.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05910710 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 20 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05910710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing